Modelling Methods of Economic Evaluations of HIV Testing Strategies in Sub-Saharan Africa: A Systematic Review.
Journal
Applied health economics and health policy
ISSN: 1179-1896
Titre abrégé: Appl Health Econ Health Policy
Pays: New Zealand
ID NLM: 101150314
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
accepted:
04
12
2022
medline:
2
6
2023
pubmed:
1
3
2023
entrez:
28
2
2023
Statut:
ppublish
Résumé
Economic evaluations, a decision-support tool for policy makers, will be crucial in planning and tailoring HIV prevention and treatment strategies especially in the wake of stalled and decreasing funding for the global HIV response. As HIV testing and treatment coverage increase, case identification becomes increasingly difficult and costly. Determining which subset of the population these strategies should be targeted to becomes of vital importance as well. Generating quality economic evidence begins with the validity of the modelling approach and the model structure employed. This study synthesises and critiques the reporting around modelling methodology of economic models in the evaluation of HIV testing strategies in sub-Saharan Africa. The following databases were searched from January 2000 to September 2020: MEDLINE, Embase, Scopus, EconLit and Global Health. Any model-based economic evaluation of a unique HIV testing strategy conducted in sub-Saharan Africa presenting a cost-effectiveness measure published from 2013 onwards was eligible. Data were extracted around three components: general study characteristics; economic evaluation design; and quality of model reporting using a novel tool developed for the purposes of this study. A total of 21 studies were included; 10 cost-effectiveness analyses, 11 cost-utility analyses. All but one study was conducted in Eastern and Southern Africa. Modelling approaches for HIV testing strategies can be broadly characterised as static aggregate models (3/21), static individual models (6/21), dynamic aggregate models (5/21) and dynamic individual models (7/21). Adequate reporting around data handling was the highest of the three categories assessed (74%), and model validation, the lowest (45%). Limitations to model structure, justification of chosen time horizon and cycle length, and description of external model validation process were all adequately reported in less than 40% of studies. The predominant limitation of this review relates to the potential implications of the narrow inclusion criteria. This review is the first to synthesise economic evaluations of HIV testing strategies in sub-Saharan Africa. The majority of models exhibited dynamic, stochastic and individual properties. Model reporting against the 13 criteria in our novel tool was mixed. Future model-based economic evaluations of HIV testing strategies would benefit from transparency around the choice of modelling approach, model structure, data handling procedures and model validation techniques.
Sections du résumé
BACKGROUND AND OBJECTIVE
Economic evaluations, a decision-support tool for policy makers, will be crucial in planning and tailoring HIV prevention and treatment strategies especially in the wake of stalled and decreasing funding for the global HIV response. As HIV testing and treatment coverage increase, case identification becomes increasingly difficult and costly. Determining which subset of the population these strategies should be targeted to becomes of vital importance as well. Generating quality economic evidence begins with the validity of the modelling approach and the model structure employed. This study synthesises and critiques the reporting around modelling methodology of economic models in the evaluation of HIV testing strategies in sub-Saharan Africa.
METHODS
The following databases were searched from January 2000 to September 2020: MEDLINE, Embase, Scopus, EconLit and Global Health. Any model-based economic evaluation of a unique HIV testing strategy conducted in sub-Saharan Africa presenting a cost-effectiveness measure published from 2013 onwards was eligible. Data were extracted around three components: general study characteristics; economic evaluation design; and quality of model reporting using a novel tool developed for the purposes of this study.
RESULTS
A total of 21 studies were included; 10 cost-effectiveness analyses, 11 cost-utility analyses. All but one study was conducted in Eastern and Southern Africa. Modelling approaches for HIV testing strategies can be broadly characterised as static aggregate models (3/21), static individual models (6/21), dynamic aggregate models (5/21) and dynamic individual models (7/21). Adequate reporting around data handling was the highest of the three categories assessed (74%), and model validation, the lowest (45%). Limitations to model structure, justification of chosen time horizon and cycle length, and description of external model validation process were all adequately reported in less than 40% of studies. The predominant limitation of this review relates to the potential implications of the narrow inclusion criteria.
CONCLUSIONS
This review is the first to synthesise economic evaluations of HIV testing strategies in sub-Saharan Africa. The majority of models exhibited dynamic, stochastic and individual properties. Model reporting against the 13 criteria in our novel tool was mixed. Future model-based economic evaluations of HIV testing strategies would benefit from transparency around the choice of modelling approach, model structure, data handling procedures and model validation techniques.
Identifiants
pubmed: 36853553
doi: 10.1007/s40258-022-00782-5
pii: 10.1007/s40258-022-00782-5
doi:
Types de publication
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
585-601Subventions
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
UNAIDS. Global HIV & AIDS statistics: fact sheet. 2022. https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf . Accessed 28 Dec 2022.
WHO. Key facts HIV. 2022. https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/key-facts-hiv-2021-26july2022.pdf?sfvrsn=8f4e7c93_5 . Accessed 28 Dec 2022.
CADTH. Health technology assessment and optimal use: medical devices; diagnostic tests; medical, surgical, and dental procedures. 2015. https://www.cadth.ca/sites/default/files/pdf/HTA_OU_Topic_ID_and_Prioritization_Process.pdf . Accessed 23 Feb 2023.
UNAIDS. UNAIDS global AIDS update 2022. 2022. https://www.unaids.org/sites/default/files/media_asset/2022-global-aids-update_en.pdf . Accessed 28 Dec 2022.
Obermeyer CM, Neuman M, Hardon A, et al. Socio-economic determinants of HIV testing and counselling: a comparative study in four African countries. Trop Med Int Health. 2012;18(9):1110–8. https://doi.org/10.1111/tmi.12155 .
doi: 10.1111/tmi.12155
Jooste S, Mabaso M, Taylor M, North A, Shean Y, Simbayi LC. Socio-economic differences in the uptake of HIV testing and associated factors in South Africa. BMC Public Health. 2021;21(1):1591. https://doi.org/10.1186/s12889-021-11583-1 .
doi: 10.1186/s12889-021-11583-1
pubmed: 34445996
pmcid: 8390264
Lankowski AJ, Siedner MJ, Bangsberg DR, Tsai AC. Impact of geographic and transportation-related barriers on HIV outcomes in sub-Saharan Africa: a systematic review. AIDS Behav. 2014;18(7):1199–223. https://doi.org/10.1007/s10461-014-0729-8 .
doi: 10.1007/s10461-014-0729-8
pubmed: 24563115
pmcid: 4047127
Mwisongo A, Mohlabane N, Tutshana B, Peltzer K. Barriers and facilitators associated with HIV testing uptake in South African health facilities offering HIV counselling and testing. Health SA Gesondheid. 2016;21(1):86–95.
Nnko S, Kuringe E, Nyato D, et al. Determinants of access to HIV testing and counselling services among female sex workers in sub-Saharan Africa: a systematic review. BMC Public Health. 2019;19(1):15. https://doi.org/10.1186/s12889-018-6362-0 .
doi: 10.1186/s12889-018-6362-0
pubmed: 30611219
pmcid: 6321716
Sandfort TGM, Dominguez K, Kayange N, et al. HIV testing and the HIV care continuum among sub-Saharan African men who have sex with men and transgender women screened for participation in HPTN 075. PLoS ONE. 2019;14(5):e0217501. https://doi.org/10.1371/journal.pone.0217501 .
doi: 10.1371/journal.pone.0217501
pubmed: 31150447
pmcid: 6544251
Hatzold K, Gudukeya S, Mutseta MN, et al. HIV self-testing: breaking the barriers to uptake of testing among men and adolescents in sub-Saharan Africa, experiences from STAR demonstration projects in Malawi, Zambia and Zimbabwe. J Int AIDS Soc. 2019;22(Suppl. 1):e25244. https://doi.org/10.1002/jia2.25244 .
doi: 10.1002/jia2.25244
pubmed: 30907505
pmcid: 6432104
Indravudh PP, Sibanda EL, d'Elbee M, et al. I will choose when to test, where I want to test’: investigating young people’s preferences for HIV self-testing in Malawi and Zimbabwe. AIDS. 2017;31(Suppl. 3):S203–12. https://doi.org/10.1097/QAD.0000000000001516 .
doi: 10.1097/QAD.0000000000001516
pubmed: 28665878
Tran BX, Nguyen LH, Turner HC, et al. Economic evaluation studies in the field of HIV/AIDS: bibliometric analysis on research development and scopes (GAPRESEARCH). BMC Health Serv Res. 2019;19(1):834. https://doi.org/10.1186/s12913-019-4613-0 .
doi: 10.1186/s12913-019-4613-0
pubmed: 31727059
pmcid: 6854742
Drummond MF, Sculpher MJ, Torrance GW, O’’brien BJ. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.
Morris S. A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy. Health Econ. 1997;6(6):589–601. https://doi.org/10.1002/(sici)1099-1050(199711)6:6%3c589::aid-hec286%3e3.0.co;2-d .
doi: 10.1002/(sici)1099-1050(199711)6:6<589::aid-hec286>3.0.co;2-d
pubmed: 9466141
Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15(12):1295–310. https://doi.org/10.1002/hec.1148 .
doi: 10.1002/hec.1148
pubmed: 16941543
Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy. 2004;9(2):110–8. https://doi.org/10.1258/135581904322987535 .
doi: 10.1258/135581904322987535
pubmed: 15099459
Chhatwal J, He T. Economic evaluations with agent-based modelling: an introduction. Pharmacoeconomics. 2015;33(5):423–33. https://doi.org/10.1007/s40273-015-0254-2 .
doi: 10.1007/s40273-015-0254-2
pubmed: 25609398
Hoang VP, Shanahan M, Shukla N, et al. A systematic review of modelling approaches in economic evaluations of health interventions for drug and alcohol problems. BMC Health Serv Res. 2016;16:127.
doi: 10.1186/s12913-016-1368-8
pubmed: 27074871
pmcid: 4831174
Zhao J, Du S, Zhu Y, Liang Y, Lu J, Chang F. A systematic review of health economic evaluation on targeted therapies for first-line treatment of metastatic non-small cell lung cancer (NSCLC): quality evaluation. Cancer Manag Res. 2020;12:4357–68. https://doi.org/10.2147/CMAR.S248471 .
doi: 10.2147/CMAR.S248471
pubmed: 32606931
pmcid: 7293415
Johri M, Ako-Arrey D. The cost-effectiveness of preventing mother-to-child transmission of HIV in low- and middle-income countries: systematic review. Cost Eff Resour Alloc. 2011;9:3. https://doi.org/10.1186/1478-7547-9-3 .
doi: 10.1186/1478-7547-9-3
pubmed: 21306625
pmcid: 3045936
Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, Hankins C. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med. 2013;10(3):e1001401. https://doi.org/10.1371/journal.pmed.1001401 .
doi: 10.1371/journal.pmed.1001401
pubmed: 23554579
pmcid: 3595225
Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1. https://doi.org/10.1186/2046-4053-4-1 .
doi: 10.1186/2046-4053-4-1
pubmed: 25554246
pmcid: 4320440
Arber M, Glanville J, Isojarvi J, et al. Which databases should be used to identify studies for systematic reviews of economic evaluations. Int J Technol Assess Health Care. 2018;34(6):547–54. https://doi.org/10.1017/S0266462318000636 .
doi: 10.1017/S0266462318000636
pubmed: 30442221
WorldBank. Data: sub-Saharan Africa. 2019. https://data.worldbank.org/country/ZG . Accessed 28 Dec 2022.
WorldBank. The world by income and region. 2020. https://datatopics.worldbank.org/world-development-indicators/the-world-by-income-and-region.html . Accessed 28 Dec 2022.
Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health. 2013;16(2):e1-5. https://doi.org/10.1016/j.jval.2013.02.010 .
doi: 10.1016/j.jval.2013.02.010
pubmed: 23538200
Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2002;25:1. https://doi.org/10.1016/j.jval.2021.11.1351 .
doi: 10.1016/j.jval.2021.11.1351
Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003;6(1):9–17. https://doi.org/10.1046/j.1524-4733.2003.00234.x .
doi: 10.1046/j.1524-4733.2003.00234.x
pubmed: 12535234
Wall KM, Inambao M, Kilembe W, et al. HIV testing and counselling couples together for affordable HIV prevention in Africa. Int J Epidemiol. 2019;48(1):217–27. https://doi.org/10.1093/ije/dyy203 .
doi: 10.1093/ije/dyy203
pubmed: 30358840
Olney JJ, Braitstein P, Eaton JW, et al. Evaluating strategies to improve HIV care outcomes in Kenya: a modelling study. Lancet HIV. 2016;3(12):e592-600. https://doi.org/10.1016/S2352-3018(16)30120-5 .
doi: 10.1016/S2352-3018(16)30120-5
pubmed: 27771231
pmcid: 5121132
Johnson LF, van Rensburg C, Govathson C, Meyer-Rath G. Optimal HIV testing strategies for South Africa: a model-based evaluation of population-level impact and cost-effectiveness. Sci Rep. 2019;9(1):12621. https://doi.org/10.1038/s41598-019-49109-w .
doi: 10.1038/s41598-019-49109-w
pubmed: 31477764
pmcid: 6718403
Luong Nguyen LB, Yazdanpanah Y, Maman F, et al. Voluntary community human immunodeficiency virus testing, linkage, and retention in care interventions in Kenya: modeling the clinical impact and cost-effectiveness. Clin Infect Dis. 2018;67(5):719–26. https://doi.org/10.1093/cid/ciy173 .
doi: 10.1093/cid/ciy173
pubmed: 29746619
pmcid: 6094004
Sharma M, Farquhar C, Ying R, et al. Modeling the cost-effectiveness of home-based HIV testing and education (HOPE) for pregnant women and their male partners in Nyanza Province, Kenya. J Acquir Immune Defic Syndr. 2016;72(Suppl. 2):S174–80. https://doi.org/10.1097/QAI.0000000000001057 .
doi: 10.1097/QAI.0000000000001057
pubmed: 27355506
pmcid: 5113236
Smith JA, Sharma M, Levin C, et al. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis. Lancet HIV. 2015;2(4):e159–68. https://doi.org/10.1016/S2352-3018(15)00016-8 .
doi: 10.1016/S2352-3018(15)00016-8
pubmed: 25844394
pmcid: 4384819
McCann NC, Cohn J, Flanagan C, et al. Strengthening existing laboratory-based systems vs. investing in point-of-care assays for early infant diagnosis of HIV: a model-based cost-effectiveness analysis. J Acquir Immune Defic Syndr. 2020;84(Suppl. 1):S12-21. https://doi.org/10.1097/QAI.0000000000002384 .
doi: 10.1097/QAI.0000000000002384
pubmed: 32520910
pmcid: 7302325
Francke JA, Penazzato M, Hou T, et al. Clinical impact and cost-effectiveness of diagnosing HIV infection during early infancy in South Africa: test timing and frequency. J Infect Dis. 2016;214(9):1319–28. https://doi.org/10.1093/infdis/jiw379 .
doi: 10.1093/infdis/jiw379
pubmed: 27540110
pmcid: 5079370
Kim LH, Cohan DL, Sparks TN, Pilliod RA, Arinaitwe E, Caughey AB. The cost-effectiveness of repeat HIV testing during pregnancy in a resource-limited setting. J Acquir Immune Defic Syndr. 2013;63(2):195–200. https://doi.org/10.1097/QAI.0b013e3182895565 .
doi: 10.1097/QAI.0b013e3182895565
pubmed: 23392461
pmcid: 3653987
Sharma M, Smith JA, Farquhar C, et al. Assisted partner notification services are cost-effective for decreasing HIV burden in western Kenya. AIDS. 2018;32(2):233–41. https://doi.org/10.1097/QAD.0000000000001697 .
doi: 10.1097/QAD.0000000000001697
pubmed: 29135576
Gilbert JA, Shenoi SV, Moll AP, Friedland GH, Paltiel AD, Galvani AP. Cost-effectiveness of community-based TB/HIV screening and linkage to care in rural South Africa. PLoS ONE. 2016;11(12):e0165614. https://doi.org/10.1371/journal.pone.0165614 .
doi: 10.1371/journal.pone.0165614
pubmed: 27906986
pmcid: 5131994
Mulogo EM, Batwala V, Nuwaha F, Aden AS, Baine OS. Cost effectiveness of facility and home based HIV voluntary counseling and testing strategies in rural Uganda. Afr Health Sci. 2013;13(2):423–9. https://doi.org/10.4314/ahs.v13i2.32 .
doi: 10.4314/ahs.v13i2.32
pubmed: 24235945
pmcid: 3824487
Rutstein SE, Brown LB, Biddle AK, et al. Cost-effectiveness of provider-based HIV partner notification in urban Malawi. Health Policy Plan. 2014;29(1):115–26. https://doi.org/10.1093/heapol/czs140 .
doi: 10.1093/heapol/czs140
pubmed: 23325584
Bassett IV, Govindasamy D, Erlwanger AS, et al. Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness. PLoS ONE. 2014;9(1):e85197. https://doi.org/10.1371/journal.pone.0085197 .
doi: 10.1371/journal.pone.0085197
pubmed: 24465503
pmcid: 3898963
Olney JJ, Eaton JW, Braitstein P, Hogan JW, Hallett TB. Optimal timing of HIV home-based counselling and testing rounds in Western Kenya. J Int AIDS Soc. 2018;21(6):e25142. https://doi.org/10.1002/jia2.25142 .
doi: 10.1002/jia2.25142
pubmed: 29883052
pmcid: 5993164
Maheswaran H, Clarke A, MacPherson P, et al. Cost-effectiveness of community-based human immunodeficiency virus self-testing in Blantyre, Malawi. Clin Infect Dis. 2018;66(8):1211–21. https://doi.org/10.1093/cid/cix983 .
doi: 10.1093/cid/cix983
pubmed: 29136117
Hove-Musekwa SD, Nyabadza F, Mambili-Mamboundou H, Chiyaka C, Mukandavire Z. Cost-effectiveness analysis of hospitalization and home-based care strategies for people living with HIV/AIDS: the case of Zimbabwe. Int Sch Res Notices. 2015. https://doi.org/10.1155/2014/836439 .
doi: 10.1155/2014/836439
Ying R, Sharma M, Celum C, et al. Home testing and counselling to reduce HIV incidence in a generalised epidemic setting: a mathematical modelling analysis. Lancet HIV. 2016;3(6):e275–82. https://doi.org/10.1016/S2352-3018(16)30009-1 .
doi: 10.1016/S2352-3018(16)30009-1
pubmed: 27240790
pmcid: 4927306
Cambiano V, Ford D, Mabugu T, et al. Assessment of the potential impact and cost-effectiveness of self-testing for HIV in low-income countries. J Infect Dis. 2015;212(4):570–7. https://doi.org/10.1093/infdis/jiv040 .
doi: 10.1093/infdis/jiv040
pubmed: 25767214
pmcid: 4512606
Cambiano V, Johnson CC, Hatzold K, et al. The impact and cost-effectiveness of community-based HIV self-testing in sub-Saharan Africa: a health economic and modelling analysis. J Int AIDS Soc. 2019;22(Suppl. 1):e25243. https://doi.org/10.1002/jia2.25243 .
doi: 10.1002/jia2.25243
pubmed: 30907498
pmcid: 6432108
Phillips AN, Cambiano V, Nakagawa F, et al. Cost-per-diagnosis as a metric for monitoring cost-effectiveness of HIV testing programmes in low-income settings in southern Africa: health economic and modelling analysis. J Int AIDS Soc. 2019;22(7):e25325. https://doi.org/10.1002/jia2.25325 .
doi: 10.1002/jia2.25325
pubmed: 31287620
pmcid: 6615491
Wilkinson T, Sculpher MJ, Claxton K, et al. The International Decision Support Initiative reference case for economic evaluation: an aid to thought. Value Health. 2016;19(8):921–8. https://doi.org/10.1016/j.jval.2016.04.015 .
doi: 10.1016/j.jval.2016.04.015
pubmed: 27987641
Caro JJ, Briggs AH, Siebert U, Kuntz KM, ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices–overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Med Decis Making. 2012;32(5):667–77. https://doi.org/10.1177/0272989X12454577 .
doi: 10.1177/0272989X12454577
pubmed: 22990082
Saramago P, Manca A, Sutton AJ. Deriving input parameters for cost-effectiveness modeling: taxonomy of data types and approaches to their statistical synthesis. Value Health. 2012;15(5):639–49. https://doi.org/10.1016/j.jval.2012.02.009 .
doi: 10.1016/j.jval.2012.02.009
pubmed: 22867772
Arriola L, Hyman JM. Sensitivity analysis for uncertainty quantification in mathematical models. In: Chowell G, Hyman JM, Bettencourt LMA, Castillo-Chavez C, editors. Mathematical and statistical estimation approaches in epidemiology. Dordrecht: Springer, Netherlands; 2009. p. 195–247.
doi: 10.1007/978-90-481-2313-1_10
Eddy DM, Hollingworth W, Caro JJ, et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med Decis Making. 2012;32(5):733–43. https://doi.org/10.1177/0272989X12454579 .
doi: 10.1177/0272989X12454579
pubmed: 22990088
Jit M, Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: a primer. Pharmacoeconomics. 2011;29(5):371–86. https://doi.org/10.2165/11539960-000000000-00000 .
doi: 10.2165/11539960-000000000-00000
pubmed: 21504239
Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics. 2008;26(3):191–215. https://doi.org/10.2165/00019053-200826030-00004 .
doi: 10.2165/00019053-200826030-00004
pubmed: 18282015
Uthman OA, Popoola TA, Uthman MM, Aremu O. Economic evaluations of adult male circumcision for prevention of heterosexual acquisition of HIV in men in sub-Saharan Africa: a systematic review. PLoS ONE. 2010;5(3):e9628. https://doi.org/10.1371/journal.pone.0009628 .
doi: 10.1371/journal.pone.0009628
pubmed: 20224784
pmcid: 2835757
Karnon J, Orji N. Option B+ for the prevention of mother-to-child transmission of HIV infection in developing countries: a review of published cost-effectiveness analyses. Health Policy Plan. 2016;31(8):1133–41. https://doi.org/10.1093/heapol/czw025 .
doi: 10.1093/heapol/czw025
pubmed: 27016949
Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13(4):397–409. https://doi.org/10.2165/00019053-199813040-00003 .
doi: 10.2165/00019053-199813040-00003
pubmed: 10178664
Vynnycky E, White RG. An introduction to infectious disease modelling. Oxford: Oxford University Press; 2011.
Mishra S, Pickles M, Blanchard JF, Moses S, Shubber Z, Boily MC. Validation of the modes of transmission model as a tool to prioritize HIV prevention targets: a comparative modelling analysis. PLoS ONE. 2014;9(7):e101690. https://doi.org/10.1371/journal.pone.0101690 .
doi: 10.1371/journal.pone.0101690
pubmed: 25014543
pmcid: 4090151
Glass T, Myer L, Lesosky M. The role of HIV viral load in mathematical models of HIV transmission and treatment: a review. BMJ Glob Health. 2020;5(1):e001800. https://doi.org/10.1136/bmjgh-2019-001800 .
doi: 10.1136/bmjgh-2019-001800
pubmed: 32133165
pmcid: 7042590
Shoko C, Chikobvu D, Bessong PO. A Markov model to estimate mortality due to HIV/AIDS using viral load levels-based states and CD4 cell counts: a principal component analysis approach. Infect Dis Ther. 2018;7(4):457–71. https://doi.org/10.1007/s40121-018-0217-y .
doi: 10.1007/s40121-018-0217-y
pubmed: 30390205
pmcid: 6249178
Garnett GP. An introduction to mathematical models in sexually transmitted disease epidemiology. Sex Transm Infect. 2002;78(1):7–12. https://doi.org/10.1136/sti.78.1.7 .
doi: 10.1136/sti.78.1.7
pubmed: 11872850
pmcid: 1763694
Culyer A, Chalkidou K, Teerawattananon Y, Santatiwongchai B. Rival perspectives in health technology assessment and other economic evaluations for investing in global and national health Who decides? Who pays? F1000Res. 2018;7:72. https://doi.org/10.12688/f1000research.13284.1 .
doi: 10.12688/f1000research.13284.1
pubmed: 29904588
pmcid: 5961761
Khorsan R, Crawford C. How to assess the external validity and model validity of therapeutic trials: a conceptual approach to systematic review methodology. Evid Based Complement Alternat Med. 2014. https://doi.org/10.1155/2014/694804 .
doi: 10.1155/2014/694804
pubmed: 24959192
pmcid: 4052625
Dekkers OM, von Elm E, Algra A, Romijn JA, Vandenbroucke JP. How to assess the external validity of therapeutic trials: a conceptual approach. Int J Epidemiol. 2010;39(1):89–94. https://doi.org/10.1093/ije/dyp174 .
doi: 10.1093/ije/dyp174
pubmed: 19376882